Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.50 |
| ▸ | CDK4 | P11802 | 1/20 | 0.50 |
| ▸ | CCND1 | P24385 | 1/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL404854 | 0.86 | NR4A2 (0.60) | NR4A2GABRA1GABRB2GABRB1GABRA3 | |
| SCHEMBL1994694 | 0.86 | ALDH1A1 (0.58) | ALDH1A1KDM4EGABRA1GABRB2CDK4 | |
| SCHEMBL1993247 | 0.86 | GABRA1 (0.67) | NR4A2GABRA1GABRB2GABRB1GABRA3 | |
| SCHEMBL6030284 | 0.85 | NR4A2 (0.73) | LMNARAB9ANR4A2ALDH1A1KDM4E | |
| SCHEMBL830179 | 0.85 | NR4A2 (0.73) | LMNARAB9ANR4A2ALDH1A1KDM4E | |
| SCHEMBL13727294 | 0.85 | LMNA (0.64) | LMNARAB9ANR4A2ALDH1A1KDM4E | |
| SCHEMBL462496 | 0.83 | NPSR1 (0.47) | ALDH1A1HSD17B10GABRA1GABRB2GABRB1 | |
| SCHEMBL368012 | 0.82 | GABRA1 (0.58) | LMNANR4A2ALDH1A1GABRA1GABRB2 | |
| SCHEMBL29790938 | 0.82 | GABRA1 (0.58) | LMNANR4A2ALDH1A1GABRA1GABRB2 | |
| SCHEMBL4061163 | 0.80 | GABRA1 (0.51) | GABRA1GABRB2GABRB1GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | ALCON RESEARCH, LTD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | LMNA 4599/4885RAB9A 1530/4885NR4A2 755/4885 |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | LMNA 4599/4885RAB9A 1530/4885NR4A2 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.